Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 6/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.56 |
| ▸ | CASP2 | P42575 | 1/20 | 0.55 |
| ▸ | SELP | P16109 | 1/20 | 0.53 |
| ▸ | NAAA | Q02083 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.51 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.51 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.49 |
| ▸ | CNR1 | P21554 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4458201 | 0.95 | FAAH (0.61) | FAAHMEN1KMT2ADNM1CASP2 | |
| SCHEMBL3810356 | 0.93 | CASP2 (0.65) | FAAHMEN1KMT2ADNM1CASP2 | |
| SCHEMBL5398678 | 0.90 | SELP (0.66) | FAAHMEN1KMT2ADNM1SELP | |
| SCHEMBL5962436 | 0.89 | CASP2 (0.59) | FAAHMEN1KMT2ADNM1CASP2 | |
| SCHEMBL14994265 | 0.87 | NAAA (0.63) | FAAHMEN1KMT2ADNM1CASP2 | |
| SCHEMBL8148507 | 0.87 | NAAA (0.63) | FAAHMEN1KMT2ADNM1CASP2 | |
| SCHEMBL5962582 | 0.86 | FAAH (0.71) | FAAHDNM1CASP2NAAALPAR2 | |
| SCHEMBL5962504 | 0.86 | FAAH (0.71) | FAAHDNM1CASP2NAAALPAR2 | |
| SCHEMBL5774412 | 0.86 | FAAH (0.71) | FAAHDNM1CASP2NAAALPAR2 | |
| SCHEMBL28488772 | 0.86 | FAAH (0.62) | FAAHMEN1KMT2ADNM1CASP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014200363-A1 | SPHINGOGLYCOLIPID ANALOGUES | VICTORIA LINK LIMITED (NZ) | 2014-12-18 | — | — | WO | disclosed |
| US-7029671-B1 | Method for activating human antigen-presenting cells, activated human antigen-presenting cells, and use thereof | KIRIN BREWERY COMPANY, LIMITED (JP) | 2006-04-18 | — | — | US | disclosed |
| US-20060073122-A1 | Method for activating human antigen presenting cells, activated human antigen - presenting cells, and use thereof | KIRIN BREWERY COMPANY, LIMITED | 2006-04-06 | — | — | US | disclosed |
| US-6555372-B1 | Viricides and antitumor agents | KIRIN BEER KABUSHIKI KAISHA (JP) | 2003-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060073122-A1 | Method for activating human antigen presenting cells, activated human antigen - presenting cells, and use thereof | CD69, CD14, NFATC1 | FAAH 1879/4885MEN1 3808/4885KMT2A 2670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.